BACKGROUND Nearly five decades ago, visionary scientists hypothesized that genetic
modification by exogenous DNA might be an effective treatment for inherited human …

The recent clinical successes of immunotherapy, as a result of a broader and more profound
understanding of cancer immunobiology, and the leverage of this knowledge to effectively …

In a range of human trials, viral vectors have emerged as safe and effective delivery vehicles
for clinical gene therapy, particularly for monogenic recessive disorders, but there has also …

A DNA-transfection protocol has been developed that makes use of a synthetic cationic lipid,
N-[1-(2, 3-dioleyloxy) propyl]-N, N, N-trimethylammonium chloride (DOTMA). Small …

A common feature of follicular lymphoma, the most prevalent haematological malignancy in
humans, is a chromosome translocation (t (14; 18)) that has coupled the immunoglobulin …

In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine
deaminase (ADA) gene into the T cells of two children with severe combined …

Since the introduction of Doxil® on the market nearly 20 years ago, a number of
nanomedicines have become part of treatment regimens in the clinic. With the exception of …

The concept behind gene therapy is simple—by delivering corrective genetic material to the
cells of a patient the symptoms of disease can be alleviated. But seven years after the first …

We report the development of an advanced system for transfer and expression of exogenous
genes in mammalian cells based on Moloney murine leukemia virus (Mo MuLV). Extensive …

The isolation of clones encoding the human surface protein T4, and the expression of the T4
gene in new cellular environments, have enabled us to examine the role of this protein in the …